참고문헌 (33)

1. 1 Stresser DM , Kupfer D . Monospecific antipeptide antibody to cytochrome P‐450 2B6 . Drug Metab Dispos 1999 ; 27 : 517 – 25 . 

   상세보기

2. 2 Lang T , Klein K , Fischer J , Nussler AK , Neuhaus P , Hofmann U , Eichelbaum M , Schwab M , Zanger UM . Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver . Pharmacogenetics 2001 ; 11 : 399 – 415 . 

   상세보기

3. 3 Lamba V , Lamba J , Yasuda K , Strom S , Davila J , Hancock ML , Fackenthal JD , Rogan PK , Ring B , Wrighton SA , Schuetz EG . Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression . J Pharmacol Exp Ther 2003 ; 307 : 906 – 22 . 

   상세보기

4. 4 Hesse LM , He P , Krishnaswamy S , Hao Q , Hogan K , von Moltke LL , Greenblatt DJ , Court MH . Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes . Pharmacogenetics 2004 ; 14 : 225 – 38 . 

   상세보기

5. 5 Ekins S , Wrighton SA . The role of CYP2B6 in human xenobiotic metabolism . Drug Metab Rev 1999 ; 31 : 719 – 54 . 

   상세보기

6. 6 Mo SL , Liu YH , Duan W , Wei MQ , Kanwar JR , Zhou SF . Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6 . Curr Drug Metab 2009 ; 10 : 730 – 53 . 

7. 7 Cho JY , Lim HS , Chung JY , Yu KS , Kim JR , Shin SG , Jang IJ . Haplotype structure and allele frequencies of CYP2B6 in a Korean population . Drug Metab Dispos 2004 ; 32 : 1341 – 4 . 

   상세보기

8. 8 Mehlotra RK , Ziats MN , Bockarie MJ , Zimmerman PA . Prevalence of CYP2B6 alleles in malaria‐endemic populations of West Africa and Papua New Guinea . Eur J Clin Pharmacol 2006 ; 62 : 267 – 75 . 

   상세보기

9. 9 Zanger UM , Klein K , Saussele T , Blievernicht J , Hofmann MH , Schwab M . Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance . Pharmacogenomics 2007 ; 8 : 743 – 59 . 

   상세보기

10. 10 Desta Z , Saussele T , Ward B , Blievernicht J , Li L , Klein K , Flockhart DA , Zanger UM . Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro . Pharmacogenomics 2007 ; 8 : 547 – 58 . 

    상세보기

11. 11 Turpeinen M , Nieminen R , Juntunen T , Taavitsainen P , Raunio H , Pelkonen O . Selective inhibition of CYP2B6‐catalyzed bupropion hydroxylation in human liver microsomes in vitro . Drug Metab Dispos 2004 ; 32 : 626 – 31 . 

    상세보기

12. 12 Richter T , Murdter TE , Heinkele G , Pleiss J , Tatzel S , Schwab M , Eichelbaum M , Zanger UM . Potent mechanism‐based inhibition of human CYP2B6 by clopidogrel and ticlopidine . J Pharmacol Exp Ther 2004 ; 308 : 189 – 97 . 

    상세보기

13. 13 Turpeinen M , Tolonen A , Uusitalo J , Jalonen J , Pelkonen O , Laine K . Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation . Clin Pharmacol Ther 2005 ; 77 : 553 – 9 . 

    상세보기

14. 14 Mutlib AE , Chen H , Nemeth GA , Markwalder JA , Seitz SP , Gan LS , Christ DD . Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz . Drug Metab Dispos 1999 ; 27 : 1319 – 33 . 

    상세보기

15. 15 Ward BA , Gorski JC , Jones DR , Hall SD , Flockhart DA , Desta Z . The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity . J Pharmacol Exp Ther 2003 ; 306 : 287 – 300 . 

16. 16 Ogburn ET , Jones DR , Masters AR , Xu C , Guo Y , Desta Z . Efavirenz primary and secondary metabolism in vitro and in vivo : identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7‐hydroxylation . Drug Metab Dispos 2010 ; 38 : 1218 – 29 . 

17. 17 Fuhr U , Jetter A , Kirchheiner J . Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the ‘cocktail’ approach . Clin Pharmacol Ther 2007 ; 81 : 270 – 83 . 

    상세보기

18. 18 Rohrbacher M , Kirchhof A , Geisslinger G , Lotsch J . Pyrosequencing‐based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance . Pharmacogenomics 2006 ; 7 : 995 – 1002 . 

    상세보기

19. 19 Burger D , van der Heiden I , la Porte C , van der Ende M , Groeneveld P , Richter C , Koopmans P , Kroon F , Sprenger H , Lindemans J , Schenk P , van Schaik R . Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race and CYP2B6 polymorphism . Br J Clin Pharmacol 2006 ; 61 : 148 – 54 . 

    상세보기

20. 20 Bae SK , Jeong YJ , Lee C , Liu KH . Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites . Xenobiotica 2011 ; 41 : 437 – 44 . 

    상세보기

21. 21 Cho DY , Ogburn ET , Jones D , Desta Z . Contribution of N‐glucuronidation to efavirenz elimination in vivo in the basal and rifampin‐induced metabolism of efavirenz . Antimicrob Agents Chemother 2011 ; 55 : 1504 – 9 . 

    상세보기

22. 22 Katzenmaier S , Markert C , Riedel KD , Burhenne J , Haefeli WE , Mikus G . Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy . Clin Pharmacol Ther 2011 ; 90 : 666 – 73 . 

    상세보기

23. 23 di Iulio J , Fayet A , Arab‐Alameddine M , Rotger M , Lubomirov R , Cavassini M , Furrer H , Gunthard HF , Colombo S , Csajka C , Eap CB , Decosterd LA , Telenti A . In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function . Pharmacogenet Genomics 2009 ; 19 : 300 – 9 . 

    상세보기

24. 24 Silverman RB . The Organic Chemistry of Drug Design and Drug Action , 2nd edn. Amsterdam; Boston: Elsevier Academic Press , 2004 . 

25. 25 Walsky RL , Astuccio AV , Obach RS . Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6 . J Clin Pharmacol 2006 ; 46 : 1426 – 38 . 

    상세보기

26. 26 Mukonzo JK , Roshammar D , Waako P , Andersson M , Fukasawa T , Milani L , Svensson JO , Ogwal‐Okeng J , Gustafsson LL , Aklillu E . A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single dose efavirenz population pharmacokinetics in Ugandans . Br J Clin Pharmacol 2009 ; 68 : 690 – 9 . 

    상세보기

27. 27 King J , Aberg JA . Clinical impact of patient population differences and genomic variation in efavirenz therapy . AIDS 2008 ; 22 : 1709 – 17 . 

28. 28 Habtewold A , Amogne W , Makonnen E , Yimer G , Riedel KD , Ueda N , Worku A , Haefeli WE , Lindquist L , Aderaye G , Burhenne J , Aklillu E . Long‐term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients . J Antimicrob Chemother 2011 ; 66 : 2350 – 61 . 

    상세보기

29. 29 Xu C , Ogburn ET , Guo Y , Desta Z . Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro : implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo . Drug Metab Dispos 2012 ; 40 : 717 – 25 . 

30. 30 Tucker GT , Houston JB , Huang SM . Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – towards a consensus . Br J Clin Pharmacol 2001 ; 52 : 107 – 17 . 

    상세보기

31. 31 Kharasch ED , Mitchell D , Coles R . Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity . J Clin Pharmacol 2008 ; 48 : 464 – 74 . 

    상세보기

32. 32 Kirchheiner J , Klein C , Meineke I , Sasse J , Zanger UM , Murdter TE , Roots I , Brockmoller J . Bupropion and 4‐OH‐bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 . Pharmacogenetics 2003 ; 13 : 619 – 26 . 

    상세보기

33. 33 Ngaimisi E , Mugusi S , Minzi O , Sasi P , Riedel KD , Suda A , Ueda N , Janabi M , Mugusi F , Haefeli WE , Bertilsson L , Burhenne J , Aklillu E . Effect of rifampicin and CYP2B6 genotype on long‐term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis . Clin Pharmacol Ther 2011 ; 90 : 406 – 13 . 

    상세보기